Keyword results: house broker

PREMIUM CONTENT

EXPOSE: Open Orphan, the utterly objective corporate analysts at FinnCap and an invitation to front run from Walbrook PR

This is a tale which leaves no one involved, other than Open Orphan PLC (ORPH), looking like angels. It is also an invitation to you from Sam Allen at Walbrook PR to front run a broker upgrade.

Subscribe to ShareProphets to access Premium Content
AAU
AAU

Ariana – House Broker Panmure ups target to 4.37p (price now 3.2p)

A gander at the website of AIM-listed Turkish gold-producer Ariana Resources (AAU) revealed a note from house broker Panmure Gordon, which has again upped its target from 3.6p to a new mark of 4.37p. Of course, as house broker, Panumure is effectively paid to put a good gloss on its clients but it  has hardly been ramping the shares in recent years and as far as I can see there is already huge upside to that valuation, based of Panmure’s own numbers.

I3E
I3E
PREMIUM CONTENT

I am sorry but my friend Gary Newman is just plain wrong

Gary Newman is a fine chap and a fine writer who I am delighted to have as a colleague. But I must take him to task for a tweet he sent last night where he is just plain wrong. The subject is i3 Energy (i3E).

Subscribe to ShareProphets to access Premium Content
UJO
UJO

Union Jack Oil at 0.21p worth 0.55p?

Caveat 1: SP Angel which produced this note is house broker to Union Jack Oil (UJO) so is biased. Caveat 2: Zac Phillips no longer works at SP Angel and the new analyst is not fit to lick Zac's boots. Caveat 3: Chris Oil owns stacks of these shares and will sell into any spike while urging others to buy like the dirty little spiv he is.  Having said all iof that I can't fault the logic of this detailed note.

SYN
SYN

Synnovia (Plastics Capital as was) – trading statement; is a 10%+ forecast reduction really “broadly in line”?!

A trading statement from industrial components and consumables manufacturer Synnovia (SYN) - until recently Plastics Capital plc - commences that it “expects trading for the financial year ending 31 March 2019 to be broadly in line with market expectations” and includes “significant organic growth continues to be achieved across both our divisions” and “the change of the company's name to Synnovia plc has seen a smooth transition and is acting as a strong signal to our organisation to do everything reasonably possible to reduce, recycle and re-use plastic waste”. The shares have responded currently, er,… more than 8% lower, back towards 100p…

AAU
AAU

Turkish gold miner Ariana at 1.4p worth 2.82p – Panmure Gordon

Panmure Gordon is house broker to AIM-listed Turkish gold miner Ariana Resources (AAU) and is therefore not impartial – so you can takes its latest musings on Ariana with a pinch of salt if you wish. However, with the shares at 1.4p Panmure has upped its price target from 2.75p to 2.82p in the wake of Ariana’s Q3 numbers. Naturally, with a boat-load of this stock myself (so I'm not impartial either) and a target of at least 2p, I think Panmure are complete geniuses...

Professor Richard Conroy you are talking buinneach

Perhaps my Gaelic is not quite up to scratch and I am willing to stand corrected by the founder and chairman of Conroy Gold & Natural Resources (CGNR) but I am trying to say in the language of "the old country" that he is talking bollocks in today's news release.

MPL
MPL

Why a research note from a house broker is just so much shite - possibly the worst note of 2017, Arden on the Mercantile Norfolk

The house broker on AIM earns its money not from investors but from corporates. It banks £2-4,000 a month as a retainer and then makes 5% commission on any funds it raises. Lovely jubbly, coke and hookers all round. Of course that makes its research less than impartial. Prostitutes do not tell their clients that they have a small dick and so you would not expect Arden Partners to conclude that shares in Mercantile Ports & Logistics (MPL) are worthless crap, which they are. Welcome to a strong contender for the worst research note of the year to date.

Solo shares at 0.24p worth 0.91p - really? What is a Spec Buy? Is this Corporate BS?

Beaufort Securities acts as house broker to Solo Oil (SOLO) so it is paid to write research on the company. Think of the relationship as being like that as between a hooker and a punter. The punter pays the bills. The hooker assures him that he is hung like a donkey. With that minor caveat I bring you a fairly detailed note from research analyst Charles Long at Beaufort out today. Apparently the shares, now 0.24p are worth 0.91p. But Hang on Henry...

CyanConnode – Beaufort marks down to an "ex corporate" hold - does that mean sell?

AIM-listed CyanConnode – Cyan to its friends – (CYAN) again looks set for a fair ride the wrong way after Beaufort Securities drew the red pen to its speculative buy note. It is now flat – a plain hold – which to normal people means sell. Of course, Beaufort was until recently a broker to the company, but that obviously has nothing to do with it. Beaufort states:

Premaitha at 10.6p worth 18p says FinnCap - new research note

The fragrant Alice Lane, a foxy young brokerette who apparently I once reduced to tears by being so beastly, is this morning disseminating the latest FinnCap note on Premaitha (NIPT) to clients. Since it is bullish I am happy to make it up to Alice by exposing this high quality research to a wider audience, especially since we own more than a few shares. By way of balance i should say that FinnCap is house broker and therefore utterly partial and you can feel free to ignore every word of this report.

AVO
AVO

EXCLUSIVE: Sinophi accuses near insolvent AIM dog Advanced Oncotherapy of lying AGAIN

This is becoming something of a ritual. Advanced Oncotherapy (AVO) is tardy in releasing very bad news but eventually fesses up. But it misleads investors. Its (now very clearly former) partner Sinophi then, effectively, accuses it of lying. Oh dear, for the second time Sinophi has stated that (almost insolvent) Advanced is telling porkies.

AVO
AVO

Advanced Oncotherapy: the answer to evidence you committed securities fraud is not a sham video

It is now 11 days since I published details of leaked emails which showed that AIM scumbag Advanced Oncotherapy had withheld awful trading news from investors as the company launched an open offer. That is clearly securities fraud. Almost as bad, the emails showed that the timelines the company had held out to both customers in China and investors in London for product delivery were just fantasy. And that is why customers walked. Heads should have rolled. Hapless Nomad Stockdale should have forced a statement. And having told its house broker (Beaufort) that a much needed refinancing would happen by the year end, we need an update on that too. Instead...

AVO
AVO

Advanced Oncotherapy - now tell us about the additional financing you promised by the year end?

Time is running out for Advanced Oncotherapy (AVO) as it scrabbles for additional finance but this time it really needs to start telling the truth to potential backers. In fact before I reveal more leaked emails I invite it to correct some previous lies told now.

Just how useless is a house broker "buy" note: Shamed Canaccord on IGAS

This website has pointed out that AIM listed IGAS has been a slam dunk sell for more than two years but for a good few months as it warned that it would breach covenants on its bonds any moron could see that the writing was on the wall. Except loyal house broker Cannacord, shamed over the Quindell fraud, its research on this has been laughable. It shows that a buy note from a house broker, especially one as shoddy as Cannacord, is just worthless. You will remember how Canaccord fired heroic Kevin Ashton, the world's number 1 tech analyst, when he refused to write a buy note on the Quindell fraud.

Premaitha: Buy at 25p on contract news - target 31p says Panmure Gordon

Panmure Gordon is house broker to Premaitha (NIPT) so take its morning note with a pinch of salt. It is paid to say buy. However for what it is worth here is its analysis of today's news and its forecasts.

Hybridan on Optibiotix - 22% upside

Hybridan is house broker to Optibiotix (OPTI) and so its views can be largely ignored.It is paid to be bullish. But by way of background here is its post results commentary which we happen to agree with. Busted clocks and all of that. 

DSG
DSG

Dillistone Group – updated view after the fallout from interim results

Shares in recruitment software group Dillistone (DSG) have slipped back from more than 110p in July and in excess of 100p for most of last month to a current 96.5p. The company’s house broker, WH Ireland, has now updated and the following updates my view.

Blinkx – a City Broker’s buy note target price 175p – and a question or eight

In the interests of balance I report to you the pre-results “buy” note on blinkx (BLNX) from its house broker Citi. It has a target price of 175p.. The shares are now 86p. However…. 

COP
COP

Circle Oil Board Appointment – Joke of the day: LMFAO

Oh please. I am still laughing. You could not make this up. Well you could. Circle Oil (COP) has today appointed a new director Dr Keith Morris. Yes the name rings a bell. This is a scream.

Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|